Recent Updates — DCOY

Decoy Therapeutics Inc. entered into a warrant inducement agreement on September 22, 2026, with an existing institutional investor to exercise outstanding Series B Milestone Warrants for 1,184,434 shares of common stock. The company reduced the exercise price of these Existing Warrants, as well as Series A and Series C warrants, from $5.91 to $3.25 per share. The transaction closed on September 23, 2026, generating approximately $3.85 million in gross proceeds for working capital. As consideration, the investor received new unregistered warrants (New Warrants) to purchase up to 2,368,868 shares at an exercise price of $3.25 per share, exercisable immediately and expiring five years from issuance. Decoy Therapeutics Inc. operates in the biotechnology industry, pioneering Designable Multi-Antivirals (D-MAVs) using its proprietary IMP(3)ACT platform.

Decoy Therapeutics Inc. entered into a Securities Purchase Agreement on June 26, 2026, for a private placement of 592,217 shares of common stock at $5.91 per share, expected to close on June 29, 2026. The transaction includes milestone-based Series A, B, and C warrants that could provide up to $17.5 million in additional gross proceeds upon meeting specific clinical trial milestones. Decoy Therapeutics Inc. is a biotechnology company focused on developing therapeutic assets into clinical trials.